AbCellera FY2025 revenue $75.1M, net loss $146.4M; liquidity ~$700M

AbCellera Biologics Inc.

2025-FY EPS reported -$0.49 vs consensus -$0.18 ▼ miss (-176.1%)

Revenue $75.1M vs $28.8M YoY; net loss $146.4M vs $162.9M; EPS $(0.49) vs $(0.55).
Available liquidity ~$700M ($561M cash + $135M non-dilutive govt funding).
Advanced ABCL635 into Phase 2, ABCL575 in Phase 1; two candidates into IND/CTA-enabling.
Cumulative partner programs 104 (+8), molecules in clinic 19 (+3).
Appointed Sarah Noonberg, M.D., Ph.D. as Chief Medical Officer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.